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Background: Vaccination against hemorrhagic fever with renal syndrome (HFRS) has been applied successfully for
more than 20 years in China, and since 2008, the government has implemented the Expanded Program of
Immunization (EPI) in regions with high incidence. In this study, we analyzed the EPI-related changes in age
distribution in reported cases of HFRS and proposed new recommendations for prevention and control of the disease.
Methods: Data relating to incidence of HFRS, geographical location and age distribution were collected through the
China Information System for Disease Control and Prevention (CISDCP) from 2005 to 2010. Excel and SPSS 18.0
software, χ2 tests and descriptive methodology were used for analysis of the data.
Results: A total 75 434 HFRS cases were reported in 28 provinces in China between 2005 and 2010. The majority of
HFRS cases occurred in adults aged 30 to 55 and this group accounted for 68.3% of the total. With the implementation
of the immunization program, HFRS age distribution has clearly changed in recent years. The proportion of HFRS cases
among individuals targeted by EPI (16–60 years of age) decreased from 86.9% in 2005 to 81.9% in 2010. However, the
proportion of cases among the non-vaccinated group aged <16 and >60 had increased from 13.1% in 2005 to 18.1%
in 2010. Notably, in the >60 age group the proportion rose from 8.8% in 2005 to 14.7% in 2010. These differences were
statistically significant.
Conclusion: HFRS vaccination has played an important role in HFRS control and prevention in China. However, since
the proportion of HFRS cases over 60 years old has increased significantly since EPI was implemented, it is
recommended that the age limit for vaccination be reconsidered. This finding may have practical implications for more
effective HFRS vaccination in the future.
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Hemorrhagic fever with renal syndrome (HFRS), a rodent-
borne viral disease caused by Hantaviruses, is characterized
by fever, hemorrhagic manifestations and renal dysfunction
[1,2]. The Hantaviruses are usually transmitted to humans
via contact with rodent excretions such as saliva, feces
and urine [1]. There are two main species of Hantavirus in
China: the Hantaan virus (HTNV) and the Seoul virus
(SEOV) [2]. China has reported over 1.5 million cases of
HFRS since 1950 [3], and HFRS was classified as a Class B* Correspondence: wangxiaofang90@163.com
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reproduction in any medium, provided the ornotifiable communicable disease in China in 1989. Since
then, the number of annual cases throughout the country
has been recorded in the national health database that is
available for epidemiological study. Up until the end of
2010, all provinces of China, except Hainan province,
had reported HFRS cases [4-6]. The annual number of
cases in China during the last two decades constituted
approximately 90% of the total cases reported worldwide.
But the number of HFRS cases in China has experienced
a steady decline in recent years [5,7]. By 2009, the nation-
wide number of reported cases (8842 cases) had reached
its lowest level in nearly two decades.
Aimed at two species of Hantavirus (HTNV and SEOV),
a safe and effective bivalent HFRS vaccine was developedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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In 2008, the HFRS-targeted Expanded Program on Immu-
nization (EPI) was implemented by the Chinese Central
Government in order to reduce the HFRS incidence fur-
ther. Free vaccine was provided to the seven provinces
with the highest incidence, namely Heilongjiang, Jilin,
Liaoning, Shandong, Hebei, Shaanxi and Zhejiang. One
year later, in 2009, HFRS rates were found to have sig-
nificantly decreased in EPI regions, and the vaccination-
based program was further expanded to 10 other provinces:
Hunan, Jiangxi, Inner Mongolia, Hubei, Henan, Jiangsu,
Fujian, Anhui, Sichuan and Guangdong. As the number
of cases among the 16 to 60 age group accounted for
more than 80 percent of the total [13,14], and because
the Pharmacopoeia of People’s Republic of China (2005)
[15] specified that the vaccines could only be used in
persons between 16 and 60 years old, the program focused
on this age group [16]. However, the bivalent HFRS vac-
cine is also considered safe for other age groups [10].
In this study, we analyzed the reported HFRS case data
from all 17 EPI regions and analyzed the changes in age
distribution among the group targeted by EPI (16–60 years



























Figure 1 Age distribution of HFRS in China from 2005 to 2010.Methods
Data collection and statistical analysis
Data were obtained from the China Information System
for Disease Control and Prevention (CISDCP) and provin-
cial monitoring reports of previous years. This system,
established in 2004, is a web-based reporting system of
nationally notifiable infectious diseases and public health
emergencies throughout the country [17,18]. The HFRS
cases were diagnosed in the hospital or the local CDC
according to the Diagnostic Criteria for Epidemic Hemor-
rhagic Fever. Two types of cases were analyzed in our
study; clinically diagnosed patients and laboratory con-
firmed cases. Clinical diagnosis criteria included: expos-
ure history (i.e. direct or indirect exposure to rodents
and their excreta and saliva within two months prior to
onset of illness); and acute onset of disease with at least
two clinical symptoms (i.e. hemorrhagic fever, and one
or more of the signs of hypotension, oliguresis or renal
damage). Laboratory confirmed cases were diagnosed as
positive using one of the relevant laboratory tests (HFRS
IgM antibody positive, 4 fold rise of IgG antibody between
acute and convalescent phage, Hantavirus RNA positive
or isolation of Hantavirus from the patient) [19]. Individ-
ual case histories of the HFRS patients were collected
via the CISDCP according to the Nationwide Surveil-
lance Program for HFRS (try out) [20]. We obtained the
following variables for HFRS cases from 2005 to 2010:
gender, date of onset, date of birth and residential address.Analysis was carried out in Microsoft Excel. We calcu-
lated the age at onset by using date of onset and date of
birth. Then we categorized the data into <16 years, 16–
60 years and >60 years age groups by province. HFRS
annual incidence per 100 000 population for the nation
and each province were collected from the Annual Epi-
demic Report which is provided by CISDCP as the Sum-
mary Analysis of the Epidemic. Demographic data was
collected from the Basic Information System, a subsystem
of the CISDCP. The number of cases was evaluated by the
χ2 test in SPSS software to determine the statistical signifi-
cance of the differences in proportions observed before
and after the introduction of the vaccine. Since the cover-
age of CISDCP was not fully extended to the township
level in some western parts of China, only 82.2% of town-
ship hospitals were covered in 2008 [21]; at the time of
writing more than 85% have now been covered but these
data are unpublished. Although some cases may not be
reported, the evaluations on the quality of the reporting
system have shown that the effect of missing reports has
been reduced as much as possible [22,23].
Database access permission statement
The initial disease data which were obtained from the
China Information System for Disease Control and Pre-
vention (CISDCP) that is open to the staff of China CDC.
All the authors were authorized to obtain and analyze
these data, and to publish the results.
Results
HFRS age distribution in china from 2005 to 2010
The total number of HFRS cases from 2005 to 2010 in
China included in our analyses was 75 434. Cases were
reported in 28 provinces, autonomous regions and muni-
cipalities; no cases were reported in the Xizang autono-
mous regions, Qinghai or Hainan provinces during these
Table 1 HFRS cases among the EPI-targeted age group





Year 16–60† <16 >60
2005 21 281 18 501 (86.9) 911 (4.3) 1869 (8.8)
2006 15 429 13 479 (87.4) 566 (3.7) 1386 (9.0)
2007 11 248 9790 (87.0) 302 (2.7) 1156 (10.3)
2008* 9227 7890 (85.5) 254 (2.8) 1083 (11.7)
2009* 8842 7497 (84.8) 226 (2.6) 1119(12.7)
2010* 9407 7703 (81.9) 322 (3.4) 1382 (14.7)
Note. *EPI conducted; †EPI-targeted. Data presented as% of total
HFRS cases/yr.
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mately 3.15:1 (57 272/18 162); there nas been no change in
this proportion in recent years. The majority of HFRS cases
occurred in adults aged 30 to 55 (68.3%; 51 527/75 434).
This pattern was similar in all six years evaluated (Figure 1).
The proportion of HFRS cases among individuals
targeted by EPI (16–60 years of age) showed a decrease
with each year that the immunization program was con-
ducted (Table 1). The proportion of HFRS cases in the
non-EPI-targeted (non-immunized) age group increased












Provinces targeted for EPI since 2008 2005 17 402 4.93











Note. *Statistically significant decrease (p < 0.05) in the number of cases from pre-v
cases (p < 0.05) from pre-vaccine years (2005–2008).The χ2 test results for HFRS annual number of cases
of all provinces for the EPI-targeted and non-targeted
age groups indicated that there was no significant dif-
ference in number of cases during the years between
2005 and 2007 (χ2 = 1.449,P = 0.485), prior to the imple-
mentation of the EPI program. In contrast, a significant
difference was found when cases from any EPI year (2008–
2010) were compared with those from any non-EPI year
(2005–2007) (χ2 = 51.095, P <0.05).
The data evaluated from 2005–2010 included the
two non-vaccination age groups: children and early- to
mid-adolescents (<16 years), and older adults (>60 years).
When the <16 age group HFRS cases were compared
between non-EPI years (2005–2007) and EPI years (2008–
2010), it was found that the numbers did not change sig-
nificantly (P = 0.142). In contrast, the number of HFRS
cases in the >60 age group was significantly different
(P < 0.05) between non-EPI and EPI years. HFRS cases
in the older non-vaccinated population (>60 years) rose
from 8.8% in 2005 to 14.7% in 2010.
When the nationwide HFRS cases were split among
the high-incidence, EPI-targeted provinces and the
low-incidence, non-EPI provinces, it was found that
they displayed different age distribution patterns dur-
ing the study period. The proportion of HFRS re-
ported cases for the 16–60 age groups actually rose-targeted age group from 2005–2010 in Non-EPI and
er
pulation
Number of cases (%)







15 177(87.2) 742(4.3) 1483(8.5)











accine years (2005–2007). **Statistically significant decrease in the number of
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regions (Table 2).
Analysis of high-incidence, EPI-targeted provinces
Despite the implementation of EPI, HFRS cases have
remained mainly concentrated in Northeast and East China,
where the seven high-incidence provinces are located. In
2010, these seven provinces accounted for 74.3% (6978/
9407) of the total cases reported in China, and this situ-
ation had changed very little over the other five years:
81.7% in 2005 (17 383/21 281), 78.6% in 2006 (12 129/15
429), 74.5% in 2007, (8380/11 248), 75.4% in 2008 (6958/
9227) and 72.2% in 2009 (6380/8842).
Over the last three years the number of HFRS cases in
Shaanxi province has steadily increased. In 2010, the
total annual number of reported cases (2356) had in-
creased by 65% over the 2009 case number (1428), and
had the highest number of HFRS cases in any year since
2005 [5]. This might be partly explained by well-known
periodic changes in zoonoses and some social or envir-
onmental factors. Like other high-incidence provinces,
the proportion of cases in the 16–60 age groups has
declined since 2008 when EPI was first implemented in
Shaanxi. However, the proportion of HFRS cases among
the >60 age group has been substantially higher than in




















































Figure 2 Proportion of HFRS among different age groups and the inc
provinces from 2005 to 2010.HFRS cases in >60 year old Shaanxi residents increased by
67.2% (413 to 247) (Figure 2).
Heilongjiang, Jilin, Liaoning, Shandong, Hebei and
Zhejiang provinces showed a steady decline in total
HFRS cases since 2005, but the slope of this downward
trend has decreased in recent years. Moreover, the inci-
dence per 100 000 population in Liaoning, Shandong
and Zhejiang provinces rebounded slightly in 2010. In
each of these six provinces, the proportion of cases in
2010 among the respective 16–60 age groups decreased
(ranging from 0.7% in Heilongjiang to a high of 8.1% in
Shandong) and the proportion of cases in the >60 age
groups increased (ranging from 26.7% in Zhejiang to 45.9%
in Liaoning). The proportion of HFRS cases among the
respective <16 age groups did not experience any obvi-
ous changes in the years examined (Figure 2).
Discussion
As a zoonosis, HFRS shows periodic variations, which
may be one of the reasons why the number of cases de-
creased in the years 2005–2007. HFRS has also been
shown to be associated with geographical locale, employ-
ment type, living (hygiene) conditions and the epidemiology
of the rodent-vector [3,24,25]. The national implementation
of a comprehensive prevention and control strategy, in-
























































idence per 100 000 population per province in seven EPI-target
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incidence of HFRS in China.
In order to reduce the incidence further, the EPI was
implemented in 2008. When the proportions of cases
among the different HFRS age groups were analyzed, it
was found that the age distribution had changed in recent
years in the EPI regions. The group that was targeted by
EPI (16–60 years of age) experienced a significant de-
crease in the proportion of HFRS cases for each year
that EPI was implemented, suggesting that vaccination
might have played a considerable role in China’s HFRS
prevention and control. Further analysis revealed that
the proportion of cases in children less than 16 years old
was relatively unaffected during this period. Moreover,
this stable profile remained when only the <16 years old,
non-EPI-targeted HFRS cases were analyzed (<10 years old
vs. 10–16 years old, for all years examined; data not shown).
We were intrigued to discover, however, that the pro-
portion of HFRS cases in the population over 60 years old
in EPI-targeted provinces had increased annually from
2008 to 2010. In fact, Shandong province had 20.2% of its
HFRS cases in the >60 age group in 2010. In stark con-
trast, the proportion of cases in the over 60 age group res-
iding in non-EPI-targeted provinces had declined in 2010.
The observation that the proportion of HFRS cases
over 60 years of age has risen in EPI-targeted regions
may be explained by the following reasons. In recent years,
more young people from rural areas have travelled to the
cities for work, increasing the necessity for the elderly who
have stayed behind to spend longer hours working in
the fields. The elderly then represent the population
most in contact with rodents and potential transmission
of Hantavirus. Furthermore, the gradual extension of
average life expectancy may have increased the propor-
tion of individuals in the >60 age group who are still
alive and working and potentially coming into contact
with Hantaviruses.. Another potential explanation may
be that China Pharmacopoeia defined the HFRS bivalent
vaccine-target group as 16–60 years old, and over the
dozen years since HFRS vaccination the current >60 years
age group might not have had sufficient opportunity for
immunization.Conclusions
The recent trend showing an increase in the proportion
of HFRS cases in individuals over 60 years of age has oc-
curred in regions undergoing rodent-based prevention
strategies and environmental remediation and in which
comprehensive public health education is widely avail-
able. Unfortunately, these non-vaccine based eradication
strategies have not been sufficient to protect this older
population from HFRS. Therefore, we recommend that
the age limit for EPI vaccination be extended beyond 60years old, as we believe it would be beneficial to HFRS
control and prevention in China.
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